Molecular characterization of type I endometrial carcinomas by Levan, Kristina
Molecular characterization of type I endometrial carcinomas 
 
 
Kristina Levan  
Department of Oncology, Institute of Clinical Sciences,  
The Sahlgrenska academy at Univerity of Gothenburg, Sweden 
Abstract 
Endometrial carcinoma is the most common malignancy in the female reproductive tract. In Sweden over 
1300 women are diagnosed every year, and although the prognosis is favourable in the majority of cases, 
about 160 patients die of the disease every year. Since the clinical outcome may be quite different for 
patients with the same diagnosis, indications are that there may be important differences among the 
tumours at the molecular level. The overall goal of our research was to contribute to the understanding in 
the molecular biology underlying endometrioid adenocarcinomas.  
 
In total, 124 type I endometrial carcinoma patients were included in the study. Methods such as CGH, FISH, 
expression array analysis and QPCR were applied to investigate molecular specificities among the tumours. 
In particular, we were looking for biomarkers useful in distinguishing more aggressive tumours that might 
require special therapy. Thus, we submitted the data to extensive statistical treatment, comparing molecular 
data from aggressive tumours (tumours that killed the patient, tumours that metastasized) with those less 
aggressive. In the CGH analysis of 98 tumours, we found that tumours from survivors on average had fewer 
chromosome aberrations than those from non-survivors. In fact, 33% of the non-metastatic tumours 
displayed no detectable aberrations, clearly a marker for good prognosis. However, we could not find any 
aberration that was entirely specific for non-survivors. A subset of 13 tumours was analyzed for gene 
amplification in a set of 15 cancer-related genes on chromosomes 2 and 7 by FISH in tumour imprints. The 
findings corresponded quite well with findings in inbred BDII rats, which are known to be genetically 
predisposed for endometrial carcinoma. These results suggest that the BDII rat provides a useful model for 
analyzing the genetic background of at least a subgroup of human endometrial carcinomas. The expression 
array analysis of 45 tumours generated a set of 218 genes that were differentially expressed between 
survivors and non-survivors. Using this set of 218 genes in a cross validation test 89% of the tumours were 
classified correctly, and in hierarchical clustering, two clusters were formed, both with over 80% 
homogeneity with respect to survival. In the latter analysis it was noted that five out of six stage I tumours 
from non-survivors, clustered in the non-survivor fraction. The gene expression analysis indicated 
dysfunction of the Rb/E2F pathway involved in the tumour progression. To investigate the potential 
involvement of this well-known pathway we aimed to characterize the protein expression of a selection of 
the proteins involved. Significant differences in protein expression of pRb in combination with E2F-1 were 
clearly related to survival. In particular, these molecular tools helped us to identify a subset of non-
survivors among tumours classified as stage I tumours. If more aggressive malignancies can be identified at 
an early stage, the indicated adjuvant treatments may dramatically improve the disease course for these 
individuals. Increased knowledge about the biological differences among individual tumours will provide 
the basis of a more accurate prognosis. In the future extended molecular information should also contribute 
to the development of improved and individually tailored treatment protocols.  
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